How to Source Peptides Safely: Pharmacy and Testing Checklist

Short answer: Only source approved peptides through a licensed pharmacy on a valid prescription, and compounded product through a registered 503A or 503B facility that will provide a certificate of analysis for the batch. Ask for third-party purity and endotoxin testing, confirm cold-chain handling, and decline anything sold with a "research use only" disclaimer.

The verification checklist

State pharmacy licence or FDA 503B registration number.
Certificate of analysis for the specific batch, not a generic PDF.
Third-party purity, identity, and endotoxin testing.
Documented cold chain from facility to door.
A named prescribing clinician and a monitoring plan.

Red flags

"Research use only — not for human consumption" on the label.
No prescription required for an injectable.
Claims of curing or reversing disease.
Prices far below pharmacy compounding cost.
No batch documentation on request.

← Back to peptide therapy: evidence, legality, and safety

Want a straight answer about whether a peptide is right for you? Kindr clinicians will tell you when the evidence supports it — and when it does not.

Start your visit →

Not ready? Ask Dot, our free AI menopause companion.

Frequently asked questions

What is the difference between 503A and 503B?

503A pharmacies compound patient-specific prescriptions. 503B outsourcing facilities register with the FDA, follow current good manufacturing practice, and may produce batches without patient-specific prescriptions.

Is a certificate of analysis enough?

Only if it is batch-specific and from an independent laboratory. Generic certificates are trivially reproduced.

Peptide therapy: evidence, legality, and safety

Evidence grading, regulation, safety, sourcing, and clinical use. Start anywhere.

Pillar guide →An honest map of a field full of marketing. Every major peptide class graded on human evidence, regulatory status, and safety — plus a candidacy quiz, an onset timeline, and the questions to ask before anyone injects anything.Peptide evidence grades →Every major peptide class graded A to D on human trial evidence.Legality and FDA status →Compounding categories, research-use-only labelling, and what is actually prescribable.Peptide safety and side effects →IGF-1 risk, sterility and contamination, drug interactions, and who should never use them.Peptides in menopause →What is realistic for midlife women — and what hormone therapy does better.How to source safely →Pharmacy registration, batch testing, cold chain, and the questions to ask.Peptide stacks, honestly assessed →Why combining unproven compounds multiplies uncertainty rather than benefit.

Other Kindr symptom hubs

The brain fog hub →The menopause sleep hub →Menopause weight gain: causes and treatment →The hot flashes hub →

Continue across the Kindr entity graph

Related evidence, peptides, and clinical tools on the same topic.

BPC-157 — tissue repair peptidePeptide
GLP-1s in menopauseJournal
TB-500 — recovery & repairPeptide
Menopause & weight gainJournal
GHK-Cu — regenerative copper peptidePeptide
SemaglutidePeptide

Sources

Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021.
Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022.
Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023.
Falutz J et al. Effects of tesamorelin on visceral adipose tissue. J Acquir Immune Defic Syndr 2010.
Kingsberg SA et al. Bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol 2019.
US Food and Drug Administration. Bulk drug substances nominated for use in compounding — 503A and 503B category listings, 2023.
Sikiric P et al. Stable gastric pentadecapeptide BPC 157 — preclinical review. Curr Pharm Des (preclinical evidence only).

Educational content only — not a substitute for professional medical advice, diagnosis, or treatment. The severity quiz is a screening aid, not a diagnosis. Reviewed by the Kindr Health clinical team · Last reviewed 2026-07-26.